NCT04078191View on ClinicalTrials.gov

Comparison of Tc 99m Tilmanocept Imaging With IHC Analysis of CD206 Expression in Synovial Tissue of Subjects With RA

PHASE2TerminatedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 14, 2021

Primary Completion Date

July 9, 2024

Study Completion Date

July 9, 2024

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tc 99m tilmanocept

Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.

Trial Locations (4)

60208

Northwestern University, Chicago

90210

Attune Health, Beverly Hills

Unknown

Barts Hospital, London

Royal Free Hospital, London

Sponsors
All Listed Sponsors
lead

Navidea Biopharmaceuticals

INDUSTRY